Related Experiment Videos
New therapies for the haemoglobinopathies
1First Department of Medicine, University of Athens, Laikon Hospital, Greece.
Journal of Internal Medicine. Supplement
|January 1, 1997
Summary
Re-activating fetal globin genes offers a promising strategy for treating hemoglobinopathies like sickle cell disease and beta-thalassemia. Current research explores various agents to re-induce fetal hemoglobin (HbF) synthesis, showing clinical benefits but requiring further study on long-term safety.
Area of Science:
- Hematology
- Molecular Biology
- Pharmacology
Background:
- Hemoglobinopathies, including sickle cell syndromes and beta-thalassemias, result in severe health complications due to abnormal hemoglobin.
- Re-activation of fetal globin genes, leading to gamma-chain production, can counteract the toxic effects of abnormal hemoglobins.
Purpose of the Study:
- To review current strategies for re-inducing fetal hemoglobin (HbF) synthesis.
- To evaluate the efficacy and safety of agents that promote HbF production for treating hemoglobinopathies.
Main Methods:
- Review of studies on agents that activate fetal globin gene promoters (e.g., butyric acid derivatives, 5' azacytidine).
- Review of studies on agents that recruit dormant erythroid precursors (e.g., erythropoietin, hydroxyurea).
- Assessment of data from cell cultures, animal models, and patient trials.
Main Results:
- Several agents have demonstrated the ability to increase HbF levels, leading to hematological, biochemical, and clinical improvements in patients.
- Two main approaches identified: direct gene activation and recruitment of fetal hemoglobin-expressing erythroid precursors.
- Agents like hydroxyurea have shown significant promise in clinical studies.
Conclusions:
- Re-induction of HbF synthesis is a viable therapeutic strategy for hemoglobinopathies.
- Further research is essential to address unresolved questions regarding long-term efficacy, optimal dosing, tolerance, toxicity, and potential mutagenicity before widespread clinical application.